SMTI at a glance
Sanara MedTech Inc. (SMTI, SEC CIK 714256) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as September 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Sanara MedTech Inc. (SMTI) reported revenue of $103.1 million (up 19.0% from FY2024) and a net loss of $37.6 million. Diluted EPS was -$4.36.
- As of September 30, 2026, 20 institutional investment managers tracked by SignalX reported holding Sanara MedTech Inc. (SMTI) shares worth $40.4 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $103.1M
- +19.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 20 funds
- $40.4M · +2 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added merger risk: FTC Second Request received October 15, 2026, extending HSR waiting period until 30 days after substantial compliance
- Regulatory risk: FTC may withhold authorization or impose conditions, restrictions, or costs that delay or prevent completion
- Financial risk: Failed merger could trigger a $9,660,336 termination fee payable to MiMedx
- Operational risk: Merger uncertainty may increase employee attrition and hiring costs
- Legal risk: Shareholder litigation could impose defense costs or obtain an injunction blocking the merger
Management Discussion & Analysis
- Revenue $28.4M, up 8% YoY from $26.3M, driven by soft tissue repair sales up 10% to $25.7M
- Gross margin approximately 93% vs 93% YoY, with bone fusion sales down 5% to $2.8M
- Net loss from continuing operations $1.3M vs $0.8M net income, Adjusted EBITDA $5.6M vs $4.9M
- Cash $16.8M vs $16.6M at December 31, 2025, operating cash flow $3.5M versus $2.8M YoY
- Outlook: cash expected to fund operations, merger costs and capital expenditures for at least 12 months; FTC Second Request extends merger review
AI summary of the SMTI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release announces Sanara MedTech’s financial results for the quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed quarterly results and management commentary for investor review
Item EX-99.1: Item EX-99.1
- Q3 revenue $28.4M, up 8%, led by soft tissue repair sales up 10% to $25.7M
- Gross margin held at 93%, while operating income fell to $0.7M from $2.9M amid $3.0M merger-related costs
Item 7.01: Regulation FD Disclosure
- THP assets sold October 6, 2026 to an unrelated third party for approximately $2 million
- Divestiture includes business software products and related intellectual property
Item 8.01: Other Events
- FTC issued a Second Request on October 15, 2026, extending HSR review of MiMedx’s proposed acquisition
- Merger waiting period now runs until 30 days after substantial compliance, unless extended or terminated earlier
AI summaries of SMTI 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SMTI
Don't miss the next SMTI filing
- Alerts as it files. A push when SMTI files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SMTI, by share count.
- Ask anything. An AI agent that reads every SMTI filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Yon Seth D | F | Sep 15, 2026 | 3,661 | $35.11 |
| TANZBERGER ERIC D | A | Jun 4, 2026 | 5,308 | - |
| Salamone Ann Beal | A | Jun 4, 2026 | 4,154 | - |
| Myers Keith G | A | Jun 4, 2026 | 4,385 | - |
| DeSutter Robert Andrew | A | Jun 4, 2026 | 5,539 | - |
| Nixon Ronald T | A | Jun 4, 2026 | 4,154 | - |
| Mack Roszell III | A | Jun 4, 2026 | 5,308 | - |
| Ortwein Sara N | A | Jun 4, 2026 | 4,616 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $86.7M | $103.1M |
| Gross Profit | - | $78.5M | $95.6M |
| Operating Income | - | -$6.7M | $7.3M |
| Net Income | - | -$9.7M | -$37.6M |
| Gross Margin | - | 90.6% | 92.7% |
| Op. Margin | - | -7.7% | 7.1% |
| Net Margin | - | -11.2% | -36.4% |
| Balance Sheet | |||
| Total Assets | $73.9M | $88.1M | $72.9M |
| Equity | - | $39.4M | $5.9M |
| ROE | - | -24.5% | -632.5% |
| Per Share | |||
| EPS | - | $-1.14 | $-4.36 |
| Cash Flow | |||
| Operating CF | - | -$24K | $6.8M |
| CapEx | $265K | $206K | $4.6M |
Source: XBRL data in Sanara MedTech Inc. (SMTI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SMTI share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 20 | $40.4M |
| Q2 2026 | 18 | $22.5M |
| Q1 2026 | 16 | $12.1M |
| Q4 2025 | 15 | $14.5M |
| Q3 2025 | 17 | $21.4M |
| Q2 2025 | 17 | $19.0M |
| Q1 2025 | 14 | $13.4M |
| Q4 2024 | 12 | $14.1M |
- BlackRock+180.7K (+73%)
- Renaissance Technologies LLC+46.7K (+69%)
- D.E. Shaw & Co+29.4K (+179%)
- Morgan Stanley+22.4K (+95%)
- Vanguard Portfolio Management LLC+10.4K (+45%)
- AQR Capital Management−86.2K (-77%)
- Goldman Sachs Group−45.2K (-61%)
- Bank of America Corp−9.6K (-60%)
- Wells Fargo & Co−1.6K (-52%)
- JPMorgan Chase & Co−229 (-9%)
- Millennium Management+37.0K
- BNY Mellon+16.1K
- Two Sigma Investments+9.7K
- PNC Financial Services+18
- Citadel Advisors LLC−36.8K
- FMR LLC (Fidelity)−1.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 129 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SMTI filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 8-K | Oct 16, 2026 | - | Analysis | - |
| 8-K | Oct 1, 2026 | - | Analysis | - |
| 4 | Sep 16, 2026 | - | - | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 8-K | Jun 9, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 4 | May 18, 2026 | - | - | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| 4 | May 5, 2026 | - | - | - |
| 4 | Apr 16, 2026 | - | - | - |
Related Health Care companies
- ALGN · Align TechnologyOrthopedic, Prosthetic & Surgical Appliances & Supplies
- AVR · Anteris Technologies Global Corp.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- AVNS · AVANOS MEDICAL, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- EW · Edwards LifesciencesOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ENOV · Enovis CORPOrthopedic, Prosthetic & Surgical Appliances & Supplies
- INGN · Inogen IncOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ISRG · Intuitive SurgicalOrthopedic, Prosthetic & Surgical Appliances & Supplies
- LAKE · LAKELAND INDUSTRIES INCOrthopedic, Prosthetic & Surgical Appliances & Supplies
SMTI SEC filings: frequently asked questions
Which institutions hold SMTI stock?
As of September 30, 2026, the largest Sanara MedTech Inc. (SMTI) holders among the 13F filers tracked by SignalX were BlackRock ($15.1 million), Vanguard Capital Management LLC ($6.8 million), Renaissance Technologies LLC ($4.0 million), State Street Corp ($2.4 million), Morgan Stanley ($1.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SMTI's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Sanara MedTech Inc. (SMTI) reported revenue of $103.1 million (up 19.0% from FY2024) and a net loss of $37.6 million. Diluted EPS was -$4.36. The figures come from the XBRL data in the 10-K.
What did SMTI report in its latest 8-K?
Sanara MedTech Inc. (SMTI) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Sanara MedTech’s financial results for the quarter ended September 30, 2026.
What are the latest SMTI SEC filings?
Sanara MedTech Inc. (SMTI) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on September 16, 2026.
What is SMTI's SEC CIK number?
Sanara MedTech Inc. (SMTI)'s SEC Central Index Key (CIK) is 714256. EDGAR lists every SMTI filing under that number.
Ask anything about SMTI
The research agent reads SMTI's filings, financials, insider trades and 13F holders, then answers with sources.